AIXC - Qualigen Therapeutics, Inc.

1.125
0.075   6.667%

Share volume: 20,858
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$1.05
0.07
0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
40%
Profitability 35%
Dept financing 43%
Liquidity 58%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.32%
1 Month
-17.88%
3 Months
-55.00%
6 Months
-33.43%
1 Year
-63.71%
2 Year
174.39%
Key data
Stock price
$1.12
P/E Ratio 
N/A
DAY RANGE
$1.08 - $1.16
EPS 
-$6.58
52 WEEK RANGE
$0.92 - $8.81
52 WEEK CHANGE
-$65.28
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
5.160 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
3.61
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$96,948
AVERAGE 30 VOLUME 
$80,117
Company detail
CEO: Michael S. Poirier
Region: US
Website: qualigeninc.com
Employees: 50
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Qualigen Therapeutics, Inc. develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers.

Recent news